Is Buying Seattle Genetics Inc (NASDAQ:SGEN) Here Good Idea?

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

Investors sentiment decreased to 1.24 in Q2 2018. Its down 0.37, from 1.61 in 2018Q1. It fall, as 23 investors sold Seattle Genetics, Inc. shares while 68 reduced holdings. 41 funds opened positions while 72 raised stakes. 160.01 million shares or 0.31% more from 159.52 million shares in 2018Q1 were reported.
Washington invested 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Cap Int Ca owns 77,605 shares or 0.79% of their US portfolio. Pnc Fincl Grp Incorporated invested 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Rhenman Partners Asset Ab reported 230,000 shares or 1.56% of all its holdings. Moreover, Nordea Mngmt Ab has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Old Mutual Customised Solutions (Proprietary) Limited invested 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Stanley, a Alabama-based fund reported 14,551 shares. Sg Americas Limited Company holds 0.07% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 116,144 shares. 3,770 were reported by World Asset Mgmt. Ubs Asset Mngmt Americas has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Tekla Capital Management Ltd holds 0.7% or 279,417 shares in its portfolio. Badgley Phelps And Bell invested in 4,450 shares. Legal & General Grp Incorporated Public Ltd Liability Corporation, United Kingdom-based fund reported 123,999 shares. 557,000 were accumulated by Eventide Asset Mgmt Limited Liability Co. University Of Notre Dame Du Lac invested 0.62% in Seattle Genetics, Inc. (NASDAQ:SGEN).

Since May 31, 2018, it had 0 insider buys, and 14 sales for $13.57 million activity. $306,058 worth of stock was sold by LIU JEAN I on Monday, August 27. On Monday, August 27 HIMES VAUGHN B sold $410,502 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 5,530 shares. On Tuesday, June 12 Cline Darren S sold $831,688 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 12,054 shares. On Monday, August 27 the insider SIMPSON TODD E sold $402,856.

The stock of Seattle Genetics Inc (NASDAQ:SGEN) registered an increase of 1.51% in short interest. SGEN’s total short interest was 11.28 million shares in December as published by FINRA. Its up 1.51% from 11.11 million shares, reported previously. With 523,600 shares average volume, it will take short sellers 22 days to cover their SGEN’s short positions. The short interest to Seattle Genetics Inc’s float is 10.63%.

The stock decreased 0.48% or $0.3 during the last trading session, reaching $62.58. About 1.12M shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 44.99% since December 2, 2017 and is uptrending. It has outperformed by 29.37% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $10.02 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 5 analysts covering Seattle Genetics (NASDAQ:SGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Seattle Genetics has $101 highest and $6600 lowest target. $83.50’s average target is 33.43% above currents $62.58 stock price. Seattle Genetics had 6 analyst reports since June 11, 2018 according to SRatingsIntel. The firm has “Buy” rating by SunTrust given on Monday, June 11. The rating was maintained by Barclays Capital on Wednesday, October 3 with “Overweight”. Piper Jaffray maintained the stock with “Hold” rating in Tuesday, November 27 report. On Friday, October 26 the stock rating was maintained by Barclays Capital with “Overweight”. The company was maintained on Friday, July 27 by JP Morgan.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Seekingalpha.com which released: “Seattle Genetics Q3 top line up 25% – Seeking Alpha” on October 25, 2018, also Seekingalpha.com with their article: “Seattle Genetics to hold investor and analyst event on December 3 – Seeking Alpha” published on November 26, 2018, Benzinga.com published: “Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings (Nov. 25-Dec. 1) – Benzinga” on November 25, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Prnewswire.com and their article: “Advancing Clinical Trials Endeavoring to Improve Odds Against Pancreatic Cancer – PRNewswire” published on November 28, 2018 as well as Seekingalpha.com‘s news article titled: “Key events next week – healthcare – Seeking Alpha” with publication date: November 23, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.